NS-638
目录号 : GC30997
An N- and L-type calcium channel inhibitor
Cas No.:150493-34-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NS 638 is an inhibitor of the N-type voltage-gated calcium channel Cav2.2 and CNS L-type calcium channels.1 It inhibits potassium-induced calcium uptake in chick cortical synaptosomes (IC50 = 3.4 ?M) and AMPA-induced GABA release from primary chick cortical neurons (IC50 = 4.3 ?M), effects that can be blocked by the N-type calcium channel inhibitor ω-conotoxin GVIA but not the L-type calcium channel inhibitor nifedipine . It also inhibits potassium-induced calcium level increases in primary chick cerebellar granule cells (IC50 = 3.4 ?M), an effect that can be blocked by nifedipine but not ω-conotoxin GVIA. NS 638 (50 mg/kg) reduces infarct volume in a mouse model of focal ischemia induced by middle cerebral artery occlusion (MCAO) but not in a gerbil model of global ischemia induced by bilateral carotid artery occlusion (BCAO).
1.M?ller, A., Christophersen, P., Drejer, J., et al.Pharmacological profile and anti-ischemic properties of the Ca2+-channel blocker NS-638Neurol. Res.17(5)353-360(1995)
Cell experiment: | The effect of NS-638 on neuronal Ca2+-channels is evaluated using whole cell patch clamp techniques[1]. |
Animal experiment: | Mice: In the mouse middle cerebral artery occlusion model, NS-638 is administered i.p. (50 mg kg-1) at 1 h and 6 h post-ischemia, and once a day for the next two days[1]. |
References: [1]. Møller A, et al. Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60. | |
| Cas No. | 150493-34-8 | SDF | |
| Canonical SMILES | NC1=NC2=CC(C(F)(F)F)=CC=C2N1CC3=CC=C(Cl)C=C3 | ||
| 分子式 | C15H11ClF3N3 | 分子量 | 325.72 |
| 溶解度 | DMSO : ≥ 34 mg/mL (104.38 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0701 mL | 15.3506 mL | 30.7012 mL |
| 5 mM | 0.614 mL | 3.0701 mL | 6.1402 mL |
| 10 mM | 0.307 mL | 1.5351 mL | 3.0701 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet